| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 27, 2023 | 'Bayer For Her' Supporting 365 Days Conversations of Care to More Women in Asia | Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD)
SINGAPORE, Sept. 27, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division in Asia/Pacific announced today in conjunction w... |
| Sep 25, 2023 | 'Bayer For Her' Supporting 365 Days Conversations of Care to More Women in Asia | Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD)
SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division in Asia/Pacific announced today in conjunction w... |
| Feb 10, 2022 | Bayer : Receives U.S. FDA Fast Track Designation for asundexian Stroke Program | SPECIALIZED PRESS
Thursday - February 10, 2022
Not intended for U.S. and UK Media Bayer Receives U.S. FDA Fast Track Designation for asundexian Stroke Program
Berlin, February 10, 2022 - Bayer today announced that the U.S. Food and Drug Adm... |
| Feb 9, 2022 | Bayer - AskBio and Touchlight Restructure Joint Venture | Research Triangle Park, N.C. and Hampton, UK - Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzyma... |
| Feb 4, 2022 | Bayer : will discontinue phase II development candidate eliapixant | This press-release (German version) is protected by "doc-check"
SPECIALIZED PRESS
Friday - February 4, 2022 Bayer will discontinue phase II development candidate eliapixant
Review of development program led to reassessment of bene... |
| Jan 17, 2022 | Bayer : Annual Bayer Pharma Media Day 2022 | SPECIALIZED PRESS
Monday - January 17, 2022
Not intended for U.S. and UK Media Annual Bayer Pharma Media Day 2022
download
Berlin, Germany, January 17, 2022 - Bayer will host its annual Pharma Media Day on Monday, February 21st, 14.30h - 17... |
| Dec 21, 2021 | Bayer : U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in children | SPECIALIZED PRESS
Tuesday - December 21, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
downloadBlood clots
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition... |
| Dec 17, 2021 | Bayer : receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes | SPECIALIZED PRESS
Friday - December 17, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and se... |
| Dec 3, 2021 | Bayer : Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer | SPECIALIZED PRESS
Friday - December 3, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Nov 15, 2021 | Bayer : extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease | SPECIALIZED PRESS
Monday - November 15, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and se... |
| Nov 11, 2021 | New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction | SPECIALIZED PRESS
Wednesday - November 10, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and... |
| Nov 10, 2021 | Bayer Submits Aflibercept for regulatory approval in the EU and Japan for Retinopathy of Prematurity in premature babies | SPECIALIZED PRESS
Wednesday - November 10, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and... |
| Nov 8, 2021 | New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy | SPECIALIZED PRESS
Monday - November 8, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Nov 5, 2021 | Bayer to present data from cardiovascular portfolio, including analyses from the comprehensive finerenone clinical trial program, VOYAGER PAD (Xarelto™) and the VICTORIA trial (Verquvo™) | SPECIALIZED PRESS
Friday - November 5, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Oct 29, 2021 | European Patent Office maintained Bayer patent on the once-daily administration of rivaroxaban (Xarelto™) | SPECIALIZED PRESS
Friday - October 29, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Oct 27, 2021 | Bayer to present new data from comprehensive finerenone clinical trial program | SPECIALIZED PRESS
Wednesday - October 27, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ... |
| Sep 20, 2021 | Bayer : extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease | SPECIALIZED PRESS
Monday - September 20, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and s... |
| Aug 5, 2021 | Bayer : strengthens-drug-discovery-platform-through-acquisition-of-Vividion-Therapeutics | Berlin, Germany -- Bayer AG today announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targe... |
| Aug 5, 2021 | Bayer : strengthens drug discovery platform through acquisition of Vividion Therapeutics | Thursday - August 5, 2021 Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Acquisition strengthens Bayer's drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion's u... |
| May 26, 2021 | BAYER AG
Bayer : AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA | Research Triangle Park, N.C. - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that the U.S. Food & Drug Administration (FDA) has cleared its Investigational New Dr... |
| Mar 31, 2021 | Bayer, Capgemini, IBM and Flipkart Lead Roster of Speakers and Panelists at Grakn Orbit 2021 | "Following one of the most trying and innovative years for our team, the release of Grakn 2.0 has elicited tremendous excitement from the community. Grakn is enabling the realisation of their visions and empowering a whole new generati... |
| Mar 23, 2021 | BAYER AG
Bayer : receives approval for Vitrakvi™ in Japan | This press-release (German version) is protected by 'doc-check'
SPECIALIZED PRESS
Tuesday - March 23, 2021
Not intended for U.S. and UK Media Bayer receives approval for Vitrakvi™ in Japan
Precision oncology treatment Vitrakvi™ (l... |
| Oct 9, 2019 | Prolific Insilico scores up to $200M deal in China; Researchers retract paper on gene involved in CRISPR baby controversy | → Alex Zhavoronkov’s Hong Kong-based AI-shop Insilico Medicine has been buzzing with the publication of data in Nature, which showed its machine learning approach helped identify potential drugs associated with a part... |
| Nov 6, 2013 | Winners of GSK academic drug hunter program include antibiotics,tropical disease targets | Sarah Ades of Pennsylvania State University: A novel approach for an anti-microbial agent class of antibiotic for gram negative bacteria;
Dr. Rahul Kohli, University of Pennsylvania: A novel approach for the design of antibiotics to overcom... |
| Sep 11, 2013 | What’s attracting big pharma to pre-clinical deals? | Gaining rights to Inovio’s novel vaccines early in development gives Roche more flexibility to shape their development pathways, perform combination trials with its own pipeline, and also puts less upfront cash at risk, Andersen pointed out... |
| Nov 27, 2012 | Novo Nordisk boosts app armory with hemophilia gaming, blood disorder tracking apps | “We are about to launch the Novo Rocket Trooper Gaming app. This game takes the patient through a maze of asteroids and has them answer disease state information questions giving them additional turbo boosts and force fields. The objective ... |
| Sep 18, 2012 | J&J to open innovation centers in London, China, U.S. to hunt for novel, early stage deals | “This is all about catching the wave as it happens,” she said.
“The innovation centers allow us to be closer to where the innovation occurs, to access and invest in the best early stage science and technology, and to fuel our business as we... |
| Aug 24, 2011 | FDA fast-tracks Bayer’s promising prostate cancer treatment (Morning Read) | Emergency preparedness: There’s an app for that. Coincidentally in sync with yesterday’s earthquake, the Department of Health and Human Services has launched the “Lifeline Facebook App Challenge,” a contest to develop an app that would use ... |
| Novo Nordisk boosts app armory with hemophilia gaming, blood disorder tracking apps | Novo Nordisk has launched its ninth app to help hemophiliacs and caregivers track bleeding events and medications. The Danish drug developer has been deepening its blood disorder diagnostic tools aimed at healthcare professionals as well as... |
| What’s attracting big pharma to pre-clinical deals? | Roche’s move to skip over Inovio’s (NYSE: INO) late stage drugs for cervical cancer and Hepatitis C and make a beeline for its preclinical DNA vaccines for prostate cancer and Hep B was initially a little puzzling. Investors have preferred ... |
| FDA fast-tracks Bayer’s promising prostate cancer treatment (Morning Read) | Current medical news and unique business news for anyone who cares about healthcare.
Bayer gets FDA boost. The FDA granted fast-track status to Bayer Healthcare Pharmaceuticals’ experimental prostate cancer treatment designed to release rad... |
| J&J to open innovation centers in London, China, U.S. to hunt for novel, early stage deals | In a move to gain access to early stage innovation, Johnson & Johnson (NYSE:JNJ) is opening innovation centers in Europe and China as well as in Boston. Earlier this year, its Janssen pharmaceuticals division opened an innovation center... |
| Winners of GSK academic drug hunter program include antibiotics,tropical disease targets | Antibiotics to address the growing threat posed by bacteria strains resistant to currently available drugs are among the winning entries of a GlaxoSmithKline (NYSE: GSK) program to fast track academic research, according to a company statem... |